Search research articles
Contact Us
Filters
Showing results (61-70 of 106) with videos related to
Page
of 11
Sort By:
British Journal of Cancer
|
January 1, 1997
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer
P J Woll, R Basser, T Le Chevalier, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 30, 2019
High prevalence of hepatitis B and syphilis in illegal gold miners in French Guiana
M Douine, R Schaub, H Jardin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 1998
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group
H Curé, I Krakowski, A Adenis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group
J R Zalcberg, D Cunningham, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2007
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
Y Bécouarn, P Senesse, S Thézenas, et al.
Gut
|
February 1, 1994
Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives
C Cellier, T Sahmoud, E Froguel, et al.
The Journal of Infusional Chemotherapy
|
January 1, 1995
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer
M Hebbar, J Bonneterre, C Fournier, et al.
Journal of Neuro-Oncology
|
February 24, 2001
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults
H Roche, H Cure, A Adenis, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 14, 2008
Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C
Christine Rotonda, T Conroy, M Mercier, et al.
American Journal of Clinical Oncology
|
April 25, 2000
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study
M Ychou, J Y Douillard, P Rougier, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 106) with videos related to
Sort By:
Page
of 11
British Journal of Cancer
|
January 1, 1997
Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer
P J Woll, R Basser, T Le Chevalier, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 30, 2019
High prevalence of hepatitis B and syphilis in illegal gold miners in French Guiana
M Douine, R Schaub, H Jardin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 1998
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group
H Curé, I Krakowski, A Adenis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group
J R Zalcberg, D Cunningham, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2007
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer
Y Bécouarn, P Senesse, S Thézenas, et al.
Gut
|
February 1, 1994
Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives
C Cellier, T Sahmoud, E Froguel, et al.
The Journal of Infusional Chemotherapy
|
January 1, 1995
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer
M Hebbar, J Bonneterre, C Fournier, et al.
Journal of Neuro-Oncology
|
February 24, 2001
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults
H Roche, H Cure, A Adenis, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
March 14, 2008
Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C
Christine Rotonda, T Conroy, M Mercier, et al.
American Journal of Clinical Oncology
|
April 25, 2000
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study
M Ychou, J Y Douillard, P Rougier, et al.
Page
of 11